Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 277

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 277
---
 or can be easily implemented; and •have an experienced management team that can implement growth initiatives, organic and inorganic with access to a primary capital injection. These illustrative criteria were not intended to be exhaustive. APx stated in its IPO prospectus that any evaluation relating to the merits of a particular initial business combination would be based, to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may deem relevant. 130 In considering the Business Combination, the APx Board concluded that the Company met nearly all the above criteria. In particular, the APx Board considered the following positive factors, although not weighted or in any order of significance: • Competitive Strengths. The unique position of the Company in the healthcare space, supported by a unique joinder of genomics product offerings, with inroads into traditionally underserved markets as well as developed markets. The Company’s position is particularly unique, given the lack of other current market participants with the breadth of products and service offerings spanning deep genetic sequencing, microbiome analysis and artificial intelligence. Additionally, the Company’s strategy is unique relative its peers in that it maintains both a b2b and b2b2c go to market strategy, while also maintaining a partnership approach with existing and deeply embedded healthcare market participants. • Attractive Valuation. The APx Board’s determination that based on the Company’s commercial potential, underpinned by their unique product offering and multi -channeldistribution approach, as well as their intellectual property portfolios, APx’s shareholders would acquire their shares in the Company at an attractive valuation in comparison to global private and public comparable companies examined by the APx Board. • Due Diligence. The results of APx’s due diligence investigation of the Company’s conducted by APx’s management team, Sponsor group and its advisors. • Negotiated Transaction. The financial and other terms of the Business Combination Agreement are reasonable, based on the experience of APx’s management team which has extensive experience in transactions involving special purpose acquisition companies, as assisted by its legal and other advisors, do not include a cash closing condition, and are the product of arm’s -lengthnegotiations between the parties thereto. The APx Board also considered a variety of uncertainties and risk and other potentially negative factors concerning the Business Combination including, but not limited to, the following: • Benefits May Not Be Achieved. The risk that the potential benefits of the Business Combination may not be fully achieved or may not be achieved within the expected timeframe; •